|
1
|
Elder DE: Melanoma progression. Pathology.
48:147–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krathen M: Malignant melanoma: Advances in
diagnosis, prognosis, and treatment. Semin Cutan Med Surg.
31:45–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Micevic G, Theodosakis N and Bosenberg M:
Aberrant DNA methylation in melanoma: Biomarker and therapeutic
opportunities. Clin Epigenetics. 9:342017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo W, Zhu L, Zhu R, Chen Q, Wang Q and
Chen JQ: A four-DNA methylation biomarker is a superior predictor
of survival of patients with cutaneous melanoma. Elife.
8:e443102019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanemura A, Terando AM, Sim MS, van Hoesel
AQ, de Maat MF, Morton DL and Hoon DS: CpG island methylator
phenotype predicts progression of malignant melanoma. Clin Cancer
Res. 15:1801–1807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang X, Xie Z, Lei X and Gan R: Long
non-coding RNA GAS5 in human cancer. Oncol Lett. 20:2587–2594.
2020. View Article : Google Scholar
|
|
8
|
Chen L, Yang H, Xiao Y, Tang X, Li Y, Han
Q, Fu J, Yang Y and Zhu Y: LncRNA GAS5 is a critical regulator of
metastasis phenotype of melanoma cells and inhibits tumor growth in
vivo. Onco Targets Ther. 9:4075–4087. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma X, Yu L, Wang P and Yang X: Discovering
DNA methylation patterns for long non-coding RNAs associated with
cancer subtypes. Comput Biol Chem. 69:164–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng M, Sun L, Huang K, Yue X, Chen J,
Zhang Z, Zhao B and Bian E: A signature of nine lncRNA methylated
genes predicts survival in patients with glioma. Front Oncol.
11:6464092021. View Article : Google Scholar
|
|
11
|
Linnekamp JF, Butter R, Spijker R, Medema
JP and van Laarhoven HWM: Clinical and biological effects of
demethylating agents on solid tumours-a systematic review. Cancer
Treat Rev. 54:10–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Momparler RL: Epigenetic therapy of cancer
with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol. 32:443–451.
2005. View Article : Google Scholar
|
|
13
|
Rajaii F, Asnaghi L, Enke R, Merbs SL,
Handa JT and Eberhart CG: The demethylating agent 5-Aza reduces the
growth, invasiveness, and clonogenicity of uveal and cutaneous
melanoma. Invest Ophthalmol Vis Sci. 55:6178–6186. 2014. View Article : Google Scholar
|
|
14
|
Lindner DJ, Wu Y, Haney R, Jacobs BS,
Fruehauf JP, Tuthill R and Borden EC: Thrombospondin-1 expression
in melanoma is blocked by methylation and targeted reversal by
5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol.
32:123–132. 2013. View Article : Google Scholar
|
|
15
|
Wang W, Wang J, Li M, Ying J and Jing H:
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in
non-Hodgkin lymphoma. Int J Mol Med. 36:698–704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Numoto K, Yoshida A, Sugihara S, Kunisada
T, Morimoto Y, Yoneda Y, Fujita Y, Nishida K, Ouchida M and Ozaki
T: Frequent methylation of RASSF1A in synovial sarcoma and the
anti-tumor effects of 5-aza-2′-deoxycytidine against synovial
sarcoma cell lines. J Cancer Res Clin Oncol. 136:17–25. 2010.
View Article : Google Scholar
|
|
18
|
Chen L, Yang H, Yi Z, Jiang L, Li Y, Han
Q, Yang Y, Zhang Q, Yang Z, Kuang Y and Zhu Y: LncRNA GAS5
regulates redox balance and dysregulates the cell cycle and
apoptosis in malignant melanoma cells. J Cancer Res Clin Oncol.
145:637–652. 2019. View Article : Google Scholar
|
|
19
|
Bian D, Shi W, Shao Y, Li P and Song G:
Long non-coding RNA GAS5 inhibits tumorigenesis via miR-137 in
melanoma. Am J Transl Res. 9:1509–1520. 2017.PubMed/NCBI
|
|
20
|
Qi Y, Cui Q, Zhang W, Yao R, Xu D and
Zhang F: Long non-coding RNA GAS5 targeting microRNA-21 to suppress
the invasion and epithelial-mesenchymal transition of uveal
melanoma. Cancer Manag Res. 12:12259–12267. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu W, Yan Z, Hu F, Wei W, Yang C and Sun
Z: Long non-coding RNA GAS5 accelerates oxidative stress in
melanoma cells by rescuing EZH2-mediated CDKN1C downregulation.
Cancer Cell Int. 20:1162020. View Article : Google Scholar
|
|
22
|
Moore LD, Le T and Fan G: DNA methylation
and its basic function. Neuropsychopharmacology. 38:23–38. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kulis M and Esteller M: DNA methylation
and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar
|
|
24
|
Li J, Li L, Yuan H, Huang XW, Xiang T and
Dai S: Up-regulated lncRNA GAS5 promotes chemosensitivity and
apoptosis of triple-negative breast cancer cells. Cell Cycle.
18:1965–1975. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang W, Xu X, Hong L, Wang Q, Huang J and
Jiang L: Upregulation of lncRNA GAS5 inhibits the growth and
metastasis of cervical cancer cells. J Cell Physiol.
234:23571–23580. 2019. View Article : Google Scholar
|
|
26
|
Wang Y, Xin S, Zhang K, Shi R and Bao X:
Low GAS5 levels as a predictor of poor survival in patients with
lower-grade gliomas. J Oncol. 2019:17850422019. View Article : Google Scholar
|
|
27
|
Wang K, Li J, Xiong G, He G, Guan X, Yang
K and Bai Y: Negative regulation of lncRNA GAS5 by miR-196a
inhibits esophageal squamous cell carcinoma growth. Biochem Biophys
Res Commun. 495:1151–1157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Budden T, van der Westhuizen A and Bowden
NA: Sequential decitabine and carboplatin treatment increases the
DNA repair protein XPC, increases apoptosis and decreases
proliferation in melanoma. BMC Cancer. 18:1002018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tawbi HA, Beumer JH, Tarhini AA, Moschos
S, Buch SC, Egorin MJ, Lin Y, Christner S and Kirkwood JM: Safety
and efficacy of decitabine in combination with temozolomide in
metastatic melanoma: A phase I/II study and pharmacokinetic
analysis. Ann Oncol. 24:1112–1119. 2013. View Article : Google Scholar
|
|
30
|
van der Westhuizen A, Knoblauch N, Graves
MC, Levy R, Vilain RE and Bowden NA: Pilot early phase II study of
decitabine and carboplatin in patients with advanced melanoma.
Medicine (Baltimore). 99:e207052020. View Article : Google Scholar : PubMed/NCBI
|
